temozolomide has been researched along with External Ophthalmoplegia in 3 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "We report here a rare case of a young male patient presenting with a Multiple Endocrine Neoplasia Type 1 - prolactin-secreting pituitary carcinoma, controlled long-term after temozolomide withdrawal." | 7.78 | Long-term control of a MEN1 prolactin secreting pituitary carcinoma after temozolomide treatment. ( Barlier, A; Barrie, M; Brue, T; Castinetti, F; Conte-Devolx, B; Dufour, H; Morange, I; Philippon, M; Taieb, D, 2012) |
| "We report here a rare case of a young male patient presenting with a Multiple Endocrine Neoplasia Type 1 - prolactin-secreting pituitary carcinoma, controlled long-term after temozolomide withdrawal." | 3.78 | Long-term control of a MEN1 prolactin secreting pituitary carcinoma after temozolomide treatment. ( Barlier, A; Barrie, M; Brue, T; Castinetti, F; Conte-Devolx, B; Dufour, H; Morange, I; Philippon, M; Taieb, D, 2012) |
| "Temozolomide is an oral alkylating agent approved for glioblastoma multiforme treatment that has only recently shown promise in treating some pituitary tumors." | 1.37 | Temozolomide for corticotroph pituitary adenomas refractory to standard therapy. ( Delashaw, JB; Dillard, TH; Fleseriu, M; Gultekin, SH; Neuwelt, EA; Yedinak, CG, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dillard, TH | 1 |
| Gultekin, SH | 1 |
| Delashaw, JB | 1 |
| Yedinak, CG | 1 |
| Neuwelt, EA | 1 |
| Fleseriu, M | 1 |
| Philippon, M | 1 |
| Morange, I | 1 |
| Barrie, M | 1 |
| Barlier, A | 1 |
| Taieb, D | 1 |
| Dufour, H | 1 |
| Conte-Devolx, B | 1 |
| Brue, T | 1 |
| Castinetti, F | 1 |
| Harkness, KA | 1 |
| Manford, MR | 1 |
3 other studies available for temozolomide and External Ophthalmoplegia
| Article | Year |
|---|---|
Temozolomide for corticotroph pituitary adenomas refractory to standard therapy.
Topics: ACTH-Secreting Pituitary Adenoma; Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Male; Midd | 2011 |
Long-term control of a MEN1 prolactin secreting pituitary carcinoma after temozolomide treatment.
Topics: Adult; Antineoplastic Agents; Carcinoma; Combined Modality Therapy; Cranial Irradiation; Dacarbazine | 2012 |
Metastatic malignant melanoma presenting as a cavernous sinus syndrome.
Topics: Adult; Antineoplastic Agents; Biomarkers, Tumor; Blepharoptosis; Cavernous Sinus Thrombosis; Cranial | 2004 |